Bucsics Theresa, Mandorfer Mattias, Schwabl Philipp, Bota Simona, Sieghart Wolfgang, Ferlitsch Arnulf, Trauner Michael, Peck-Radosavljevic Markus, Reiberger Thomas
Division of Gastroenterology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Vienna Hepatic Hemodynamic Laboratory, Medical University of Vienna, Vienna, Austria.
J Gastroenterol Hepatol. 2015 Nov;30(11):1657-65. doi: 10.1111/jgh.13002.
Acute kidney injury (AKI) is a common complication in patients with liver cirrhosis, and its impact on the clinical course is increasingly recognized. Diagnostic classification systems for AKI in cirrhosis have been suggested. The prognostic significance of the respective AKI stages remains to be evaluated in decompensated cirrhosis with ascites.
Data of consecutive patients with cirrhosis and ascites undergoing paracentesis at a tertiary care center were analyzed. AKI was defined as an increase in serum creatinine of ≥ 0.3 mg/dL or by ≥ 50% within 7 days after paracentesis, and classified according to (i) revised Acute Kidney Injury Network (AKIN) criteria and (ii) modified AKI criteria for cirrhosis (C-AKI). In contrast to AKIN, C-AKI stage A discriminates prognosis based on an absolute creatinine cut-off at < 1.5 mg/dL versus C-AKI stage B at ≥ 1.5 mg/dL.
The final study cohort included 239 patients. Median transplant-free survival was 768 days (95% confidence interval [CI]: 331-1205 days) without AKI, 198 (0-446) in AKI-1, 91 (0-225) in AKI-2, 19 (0-40) and in AKI-3, whereas it was 89 (20-158) days in C-AKI-A, 384 (0-1063) in C-AKI-B, and 22 (7-776) in C-AKI-C. Mild AKI was already associated with significantly increased 30-day mortality (AKI-1:26.4%, C-AKI-A:33.3%) as compared with patients without AKI (14.3%), even when serum creatinine remained within normal range (< 1.2 mg/dL) we observed a significant 30-day mortality.
AKIN criteria-considering small increases in serum creatinine rather than absolute thresholds-seem to be more accurate for estimating prognosis of AKI after paracentesis than C-AKI criteria. Even patients developing AKI-1 with "normal" serum creatinine are at increased risk for mortality.
急性肾损伤(AKI)是肝硬化患者常见的并发症,其对临床病程的影响日益受到认可。已有针对肝硬化患者AKI的诊断分类系统被提出。在失代偿期肝硬化合并腹水患者中,各AKI分期的预后意义仍有待评估。
分析在一家三级医疗中心连续接受腹腔穿刺术的肝硬化合并腹水患者的数据。AKI定义为腹腔穿刺术后7天内血清肌酐升高≥0.3mg/dL或升高≥50%,并根据(i)修订的急性肾损伤网络(AKIN)标准和(ii)肝硬化的改良AKI标准(C-AKI)进行分类。与AKIN不同,C-AKI A期基于血清肌酐绝对临界值<1.5mg/dL与C-AKI B期≥1.5mg/dL来区分预后。
最终研究队列包括239例患者。无AKI患者的中位无移植生存期为768天(95%置信区间[CI]:331 - 1205天),AKI-1期为198天(0 - 446天),AKI-2期为91天(0 - 225天),AKI-3期为19天(0 - 40天),而C-AKI A期为89天(20 - 158天),C-AKI B期为384天(0 - 1063天),C-AKI C期为22天(7 - 776天)。与无AKI患者(14.3%)相比,轻度AKI已与30天死亡率显著增加相关(AKI-1期:26.4%,C-AKI A期:33.3%),即使血清肌酐仍在正常范围内(<1.2mg/dL),我们仍观察到显著的30天死亡率。
考虑血清肌酐小幅升高而非绝对阈值的AKIN标准,在估计腹腔穿刺术后AKI的预后方面似乎比C-AKI标准更准确。即使是血清肌酐“正常”的AKI-1期患者,其死亡风险也会增加。